Showing 61 to 70 of 70 results
Medicare Price Negotiations Expand to 15 Drugs, Including Ozempic and Wegovy
The Biden administration announced 15 drugs, including Ozempic and Wegovy, for Medicare price negotiations under the Inflation Reduction Act, aiming to lower drug costs for 50 million beneficiaries; the new prices are expected to take effect in January 2027, although the incoming Trump administratio...
Medicare Price Negotiations Expand to 15 Drugs, Including Ozempic and Wegovy
The Biden administration announced 15 drugs, including Ozempic and Wegovy, for Medicare price negotiations under the Inflation Reduction Act, aiming to lower drug costs for 50 million beneficiaries; the new prices are expected to take effect in January 2027, although the incoming Trump administratio...
Progress
36% Bias Score
California's Affordable Insulin Plan Faces Delays
California's plan to produce cheap insulin by 2024 is delayed due to the time needed for clinical trials and FDA approval, impacting 3.2 million diabetics and exceeding the projected timeline by at least one year.
California's Affordable Insulin Plan Faces Delays
California's plan to produce cheap insulin by 2024 is delayed due to the time needed for clinical trials and FDA approval, impacting 3.2 million diabetics and exceeding the projected timeline by at least one year.
Progress
44% Bias Score
Defeated PBM Reform Bill Fails to Address Core Issues
The FTC's July 2024 report criticized PBM practices, leading to a lawsuit; a defeated bill (HR II Section 227) attempted reform but failed to address core issues like rebates and transparency, potentially increasing costs and administrative burden.
Defeated PBM Reform Bill Fails to Address Core Issues
The FTC's July 2024 report criticized PBM practices, leading to a lawsuit; a defeated bill (HR II Section 227) attempted reform but failed to address core issues like rebates and transparency, potentially increasing costs and administrative burden.
Progress
56% Bias Score
Pharmaceutical Industry Faces 2025 Inflection Point Amidst Global Cost Pressures
Global pharmaceutical manufacturers face increasing pressure to lower drug prices in 2025 due to government regulations (e.g., the Inflation Reduction Act), payer consolidation, and consumer cost concerns; requiring manufacturers to prioritize long-term value, evidence-based decision-making, and str...
Pharmaceutical Industry Faces 2025 Inflection Point Amidst Global Cost Pressures
Global pharmaceutical manufacturers face increasing pressure to lower drug prices in 2025 due to government regulations (e.g., the Inflation Reduction Act), payer consolidation, and consumer cost concerns; requiring manufacturers to prioritize long-term value, evidence-based decision-making, and str...
Progress
44% Bias Score
Spain to Restructure Pharmaceutical Co-payments, Expand Prescribing Rights
Spain's Ministry of Health proposes a new pharmaceutical co-payment law, creating six income brackets, capping monthly expenses for low earners, expanding prescription rights for nurses and physiotherapists, prioritizing generic drugs, and granting the AEMPS more power over drug supply.
Spain to Restructure Pharmaceutical Co-payments, Expand Prescribing Rights
Spain's Ministry of Health proposes a new pharmaceutical co-payment law, creating six income brackets, capping monthly expenses for low earners, expanding prescription rights for nurses and physiotherapists, prioritizing generic drugs, and granting the AEMPS more power over drug supply.
Progress
36% Bias Score
Medicare to Negotiate Prices for Ozempic, Wegovy, and 13 Other Drugs
Medicare will negotiate prices for Ozempic, Wegovy, and 13 other drugs, impacting 5.3 million Part D users and $41 billion in drug costs, with negotiated prices effective in 2027.
Medicare to Negotiate Prices for Ozempic, Wegovy, and 13 Other Drugs
Medicare will negotiate prices for Ozempic, Wegovy, and 13 other drugs, impacting 5.3 million Part D users and $41 billion in drug costs, with negotiated prices effective in 2027.
Progress
32% Bias Score
Future of Medicare Drug Price Negotiations Uncertain Under Trump
Medicare's new drug price negotiation program, enacted under the Inflation Reduction Act, faces an uncertain future under the incoming Trump administration; while it lowered prices on 10 drugs in 2023, and aims to lower prices on 15 more in 2027, Republican efforts to repeal it are underway.
Future of Medicare Drug Price Negotiations Uncertain Under Trump
Medicare's new drug price negotiation program, enacted under the Inflation Reduction Act, faces an uncertain future under the incoming Trump administration; while it lowered prices on 10 drugs in 2023, and aims to lower prices on 15 more in 2027, Republican efforts to repeal it are underway.
Progress
52% Bias Score
Medicare Part D Drug Cost Cap Set at $2,000 Annually Starting in 2025
The Inflation Reduction Act institutes a $2,000 annual out-of-pocket cap on Medicare Part D prescription drug costs starting in 2025, benefiting over 3 million enrollees without low-income subsidies, with this number projected to reach over 4 million by 2029; insurers will cover 60% of costs in the ...
Medicare Part D Drug Cost Cap Set at $2,000 Annually Starting in 2025
The Inflation Reduction Act institutes a $2,000 annual out-of-pocket cap on Medicare Part D prescription drug costs starting in 2025, benefiting over 3 million enrollees without low-income subsidies, with this number projected to reach over 4 million by 2029; insurers will cover 60% of costs in the ...
Progress
48% Bias Score
Congress Fails to Pass PBM Reform
Congress failed to pass legislation reforming pharmacy benefit managers (PBMs), despite bipartisan efforts, leaving in place an industry criticized for opaque practices and potential conflicts of interest. The legislation aimed to increase transparency and change the compensation structure of PBMs, ...
Congress Fails to Pass PBM Reform
Congress failed to pass legislation reforming pharmacy benefit managers (PBMs), despite bipartisan efforts, leaving in place an industry criticized for opaque practices and potential conflicts of interest. The legislation aimed to increase transparency and change the compensation structure of PBMs, ...
Progress
40% Bias Score
France Approves Wegovy Reimbursement for Severely Obese Adults
France's Haute Autorité de Santé (HAS) approved Wegovy reimbursement for severely obese adults (BMI ≥35 kg/m²), following new data demonstrating reduced cardiovascular risks and approximately 17% weight loss; the drug, costing €274–€365 monthly, necessitates combined use with diet and exercise.
France Approves Wegovy Reimbursement for Severely Obese Adults
France's Haute Autorité de Santé (HAS) approved Wegovy reimbursement for severely obese adults (BMI ≥35 kg/m²), following new data demonstrating reduced cardiovascular risks and approximately 17% weight loss; the drug, costing €274–€365 monthly, necessitates combined use with diet and exercise.
Progress
36% Bias Score
Showing 61 to 70 of 70 results